Clinical Trial News and Research

RSS

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity.

21 Apr 2014

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.

21 Apr 2014

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells.

21 Apr 2014

Researchers devise new approach to treatment of Alzheimer's disease

A team of researchers from Columbia University Medical Center, Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating the potentially toxic byproduct amyloid-beta, which is thought to contribute to the development of Alzheimer's.

21 Apr 2014

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Craig Lipset, head of clinical innovation at Pfizer Inc., will join advocates of patient data accessibility to highlight the Blue Button initiative at the DIA 2014 50th Annual Meeting in San Diego.

18 Apr 2014

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.

18 Apr 2014

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Kessler Foundation has been named awardee of a three-year grant for $1.8 million from the Department of Defense Spinal Cord Injury Research Program. Gail Forrest, PT, PhD, is principal investigator for the randomized, double-blinded, controlled, multi-site clinical trial, which will test strategies to improve bone and muscle strength after spinal cord injury. Dr. Forrest is assistant director of Human Performance & Engineering Research at Kessler Foundation.

18 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

Agios begins AG-348 Phase 1 study to treat PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers.

18 Apr 2014

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer.

17 Apr 2014

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML).

17 Apr 2014

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer.

17 Apr 2014

Study: HIV-positive women respond well to vaccine against human papillomavirus

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial.

17 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.

From Baxter International Inc. 16 Apr 2014

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.

16 Apr 2014

Community efforts boost people for HIV testing and reduce new infections

Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal The Lancet Global Health.

16 Apr 2014

Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial is published in the journal Stem Cells Research and Therapy, and the approach has been shown to work in two different mouse models.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Researchers evaluate rice consumption against overall diet quality and key nutrient intakes

New research, partially funded by the U.S. Department of Agriculture and the USA Rice Federation, shows that consumers can improve their diets simply by enjoying white or brown rice as part of their daily meals.

16 Apr 2014

Clinical Trial News and Research

Evidence-based interventions provide promising strategies for reducing racial, ethnic health disparities

IV-administered ketamine effective in patients with chronic PTSD

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Researchers devise new approach to treatment of Alzheimer's disease

Pfizer to highlight Blue Button initiative at DIA 2014 Annual Meeting in San Diego

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

Agios begins AG-348 Phase 1 study to treat PK deficiency

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Researchers create clinical trial for patients with advanced lung cancer

Study: HIV-positive women respond well to vaccine against human papillomavirus

Iconic Therapeutics completes $20 million Series B-1 equity financing

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Epirus Biopharmaceuticals to merge with Zalicus

Community efforts boost people for HIV testing and reduce new infections

Genetically modified neural stem cells offer potential treatment for Alzheimer's disease

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Researchers evaluate rice consumption against overall diet quality and key nutrient intakes

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer